Facile preparation of nanomicelles using polymyxin E for enhanced antitumor effects. Issue 3 (14th February 2022)

• Record Type: Journal Article
• Authors: Lan, Xifa; Guo, Quanling; Liu, Zhiwei; Liu, Kai; He, Jinfeng; Li, Ruyu; Sun, Haotian; Yao, Wenxiu; Wang, Longgang
• Is Part Of: Journal of biomaterials science. Volume 33:Issue 3(2022)
• Page Start: 329
• Page End: 341
• Publication Date: 2022-02-14
• Subjects: Micelles -- doxorubicin -- biocompatibility -- antitumor -- release; Polymers -- Biocompatibility -- Periodicals; Biomedical materials -- Periodicals; 572.33
• DOI: 10.1080/09205063.2021.1989568
• Languages: English
• ISSNs: 0920-5063

Abstract

Abstract: Chemotherapy is a major cancer treatment that uses antitumor drugs to kill fast-growing cancer cells. Many kinds of drug carriers have been developed to deliver and achieve controlled release of small-molecule therapeutic agents. However, many therapeutic agent carriers need complex preparation process. The natural polypeptides may serve as proper drug carriers. More specifically, polymyxin E (PE) is a kind of natural antibiotic lipopeptides. It is commonly used to treat infections caused by multidrug-resistant Gram-negative bacteria. Herein, we present a facile method to prepare DOX-loaded polymyxin E micelles (PE-DOX micelles) to enhance the therapeutic effect of anticancer drug doxorubicin (DOX). The hydrodynamic sizes and zeta potential of the prepared nanomedicine (PE-DOX micelles) were 142.0 nm and 6.47 mV, respectively. The release of DOX from PE-DOX micelles was faster at pH 5.5 than that at pH 7.4. Furthermore, PE exhibited negligible cytotoxicity to A549 cells and HeLa cells within 50 μg/mL, while PE-DOX micelles caused higher cytotoxicity than that of free DOX. Moreover, the intravenously injected PE-DOX micelles showed good biocompatibility and obvious antitumor effect after 14 days' treatment in vivo . The PE-DOX micelles have great potential to be used as anticancer agent in the future. Graphical Abstract: UF0001